Improvement of refractory acyclovir-resistant herpes simplex virus type 1 infection by continuous acyclovir administration

Ikawa, Yasuhiro; Fujiki, Toshihiro; Nishimura, Ryosei; Noguchi, Kazuhiro; Koshino, Eri; Fujiki, Akiko; Fukuda, Masaki; Kuroda, Rie; Mase, Shintaro; Araki, Raita; Maeba, Hideaki; Shiraki, Kimíyasu; Yachie, Akihiro

doi:10.1016/j.jiac.2018.07.004

Cited by 6 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical studies have also demonstrated that allogeneic hematopoietic cell transplantation recipients frequently experience complications from varicella-zoster virus infection and associated complications. It was observed that continuous acyclovir administration could be the best option to treat severe HSV-1 infectious patients [4,5].…”

Section: Introductionmentioning

confidence: 99%

Pseudoboehmite as a drug delivery system for acyclovir

Peres

Sousa

Oliveira

et al. 2021

Preprint

View full text Add to dashboard Cite

Herpes simplex virus is among the most prevalent sexually transmitted infections. Acyclovir is a potent, selective inhibitor of herpes viruses and is indicated for the treatment and management of recurrent cold sores on the lips and face, genital herpes, among other diseases. The problem of the oral bioavailability of acyclovir is limited because of low permeability across the gastrointestinal membrane. Based on experiments using nanoparticles of pseudoboehmite as a drug delivery system in vitro assays it was concluded that pseudoboehmite could be used for acyclovir release. We report the synthesis of high purity pseudoboehmite from aluminium nitrate and ammonium hydroxide containing nanoparticles. Pseudoboehmite was characterized by several techniques. In vivo tests were performed with Wistar rats to compare the release of acyclovir, with and without the addition of pseudoboehmite. The administration of acyclovir with the addition of pseudoboehmite increased the drug content in the plasma of Wistar rats after 4 h administration. The toxicity of pseudoboehmite was also evaluated using the Caco-2 cell line (ATCC).

show abstract

Section: Introductionmentioning

confidence: 99%

Pseudoboehmite as a drug delivery system for acyclovir

Peres

Sousa

Oliveira

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Clinical studies have also demonstrated that allogeneic hematopoietic cell transplantation recipients frequently experience complications from varicella-zoster virus infection. It has been shown recently that continuous acyclovir administration could be the best option to treat severe HSV-1 infectious patients 4,5 . In a recent study, it has been suggested a relation between Herpesviruses and Alzheimer's disease 2 .…”

mentioning

confidence: 99%

Pseudoboehmite as a drug delivery system for acyclovir

Peres

Sousa

Oliveira

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Herpes simplex virus is among the most prevalent sexually transmitted infections. Acyclovir is a potent, selective inhibitor of herpes viruses and it is indicated for the treatment and management of recurrent cold sores on the lips and face, genital herpes, among other diseases. The problem of the oral bioavailability of acyclovir is limited because of the low permeability across the gastrointestinal membrane. The use of nanoparticles of pseudoboehmite as a drug delivery system in vitro assays is a promising approach to further the permeability of acyclovir release. Here we report the synthesis of high purity pseudoboehmite from aluminium nitrate and ammonium hydroxide containing nanoparticles, using the sol–gel method, as a drug delivery system to improve the systemic bioavailability of acyclovir. The presence of pseudoboehmite nanoparticles were verified by infrared spectroscopy, transmission electron microscopy, and X-ray diffraction techniques. In vivo tests were performed with Wistar rats to compare the release of acyclovir, with and without the addition of pseudoboehmite. The administration of acyclovir with the addition of pseudoboehmite increased the drug content by 4.6 times in the plasma of Wistar rats after 4 h administration. We determined that the toxicity of pseudoboehmite is low up to 10 mg/mL, in gel and the dried pseudoboehmite nanoparticles.

show abstract

Management of Refractory/Resistant Herpes Simplex Virus Infections in Haematopoietic Stem Cell Transplantation Recipients: A Literature Review

Sallée,

Boutolleau

2024

Reviews in Medical Virology

View full text Add to dashboard Cite

Herpes simplex virus (HSV) infections in allogeneic haematopoietic stem cell transplantation (HSCT) recipients pose significant challenges, with higher incidence, severity, and risk of emergence of resistance to antivirals due to impaired T‐cell mediated immunity. This literature review focuses on acyclovir‐refractory/resistant HSV infections in HSCT recipients. The review addresses the efficacy of antiviral prophylaxis, the incidence of acyclovir‐refractory/resistant HSV infections, and the identification of risk factors and potential prognostic impact associated with those infections. Additionally, alternative therapeutic options are discussed. While acyclovir prophylaxis demonstrates a significant benefit in reducing HSV infections in HSCT recipients and, in some cases, overall mortality, concerns arise about the emergence of drug‐resistant HSV strains. Our systematic review reports a median incidence of acyclovir‐resistant HSV infections of 16.1%, with an increasing trend in recent years. Despite limitations in available studies, potential risk factors of emergence of HSV resistance to acyclovir include human leucocyte antigen (HLA) mismatches, myeloid neoplasms and acute leukaemias, and graft‐versus‐host disease (GVHD). Limited evidences suggest a potentially poorer prognosis for allogeneic HSCT recipients with acyclovir‐refractory/resistant HSV infection. Alternative therapeutic approaches, such as foscarnet, cidofovir, topical cidofovir, optimised acyclovir dosing, and helicase‐primase inhibitors offer promising options but require further investigations. Overall, larger studies are needed to refine preventive and therapeutic strategies for acyclovir‐refractory/resistant HSV infections in allogeneic HSCT recipients and to identify those at higher risk.

show abstract

Improvement of refractory acyclovir-resistant herpes simplex virus type 1 infection by continuous acyclovir administration

Cited by 6 publications

References 9 publications

Pseudoboehmite as a drug delivery system for acyclovir

Pseudoboehmite as a drug delivery system for acyclovir

Pseudoboehmite as a drug delivery system for acyclovir

Management of Refractory/Resistant Herpes Simplex Virus Infections in Haematopoietic Stem Cell Transplantation Recipients: A Literature Review

Contact Info

Product

Resources

About